After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China
But Is Sector Becoming Overcrowded?
Executive Summary
Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
You may also be interested in...
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
A Hundred Drugs Contend: Chinese Biopharma Gains US Foothold
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.